AIM ImmunoTech Valuation
| AIM Stock | USD 1.59 0.24 17.78% |
Based on Macroaxis valuation methodology, the firm appears to be undervalued. AIM ImmunoTech shows a prevailing Real Value of $4.91 per share. The current price of the firm is $1.59. Our model approximates the value of AIM ImmunoTech from examining the firm fundamentals such as Current Valuation of 3.84 M, return on equity of -31.39, and Operating Margin of (94.12) % as well as evaluating its technical indicators and probability of bankruptcy. Key fundamental drivers impacting AIM ImmunoTech's valuation include:
Price Book 2.7248 | Enterprise Value | Enterprise Value Ebitda 0.4928 | Price Sales 34.3902 | Enterprise Value Revenue 34.2658 |
Undervalued
Today
Please note that AIM ImmunoTech's price fluctuation is unstable at this time. Calculation of the real value of AIM ImmunoTech is based on 3 months time horizon. Increasing AIM ImmunoTech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the AIM stock is determined by what a typical buyer is willing to pay for full or partial control of AIM ImmunoTech. Since AIM ImmunoTech is currently traded on the exchange, buyers and sellers on that exchange determine the market value of AIM Stock. However, AIM ImmunoTech's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.59 | Real 4.91 | Target 15.0 | Hype 1.6 | Naive 1.68 |
The intrinsic value of AIM ImmunoTech's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence AIM ImmunoTech's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of AIM ImmunoTech helps investors to forecast how AIM stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of AIM ImmunoTech more accurately as focusing exclusively on AIM ImmunoTech's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use AIM ImmunoTech's intrinsic value based on its ongoing forecasts of AIM ImmunoTech's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against AIM ImmunoTech's closest peers.
AIM ImmunoTech Cash |
|
AIM ImmunoTech Total Value Analysis
AIM ImmunoTech is presently forecasted to have company total value of 3.84 M with market capitalization of 3.85 M, debt of 2.94 M, and cash on hands of 1.7 M. Please note that company total value may be misleading and is a subject to accounting gimmicks. We encourage investors to carefully check all of the AIM ImmunoTech fundamentals before making security assessment based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
3.84 M | 3.85 M | 2.94 M | 1.7 M |
AIM ImmunoTech Investor Information
The company recorded a loss per share of 18.18. AIM ImmunoTech last dividend was issued on the 11th of June 2019. The entity had 1:100 split on the 12th of June 2025. AIM ImmunoTech may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.AIM ImmunoTech Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. AIM ImmunoTech has an asset utilization ratio of 1.97 percent. This suggests that the Company is making $0.0197 for each dollar of assets. An increasing asset utilization means that AIM ImmunoTech is more efficient with each dollar of assets it utilizes for everyday operations.AIM ImmunoTech Ownership Allocation
AIM ImmunoTech shows 3.85 percent of its outstanding shares held by insiders and 4.93 percent owned by other corporate entities.AIM ImmunoTech Profitability Analysis
The company reported the last year's revenue of 170 K. Reported Net Loss for the year was (17.32 M) with profit before taxes, overhead, and interest of 17 K.About AIM ImmunoTech Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of AIM ImmunoTech. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of AIM ImmunoTech based exclusively on its fundamental and basic technical indicators. By analyzing AIM ImmunoTech's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of AIM ImmunoTech's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of AIM ImmunoTech. We calculate exposure to AIM ImmunoTech's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of AIM ImmunoTech's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 139 K | 145.9 K | |
| Pretax Profit Margin | (101.88) | (106.98) | |
| Operating Profit Margin | (133.75) | (140.44) | |
| Net Loss | (101.88) | (106.98) | |
| Gross Profit Margin | 0.82 | 0.86 |
AIM ImmunoTech Growth Indicators
Investing in growth stocks can be very risky. If the company such as AIM ImmunoTech does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 56 M |
AIM ImmunoTech Current Valuation Indicators
AIM ImmunoTech's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final AIM ImmunoTech's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as AIM ImmunoTech, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use AIM ImmunoTech's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes AIM ImmunoTech's worth.When determining whether AIM ImmunoTech is a strong investment it is important to analyze AIM ImmunoTech's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact AIM ImmunoTech's future performance. For an informed investment choice regarding AIM Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AIM ImmunoTech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in AIM Stock, please use our How to Invest in AIM ImmunoTech guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AIM ImmunoTech. If investors know AIM will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AIM ImmunoTech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (18.18) | Revenue Per Share | Quarterly Revenue Growth (0.26) | Return On Assets | Return On Equity |
The market value of AIM ImmunoTech is measured differently than its book value, which is the value of AIM that is recorded on the company's balance sheet. Investors also form their own opinion of AIM ImmunoTech's value that differs from its market value or its book value, called intrinsic value, which is AIM ImmunoTech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AIM ImmunoTech's market value can be influenced by many factors that don't directly affect AIM ImmunoTech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AIM ImmunoTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if AIM ImmunoTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AIM ImmunoTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.